lactoferrin has been researched along with Nervous-System-Diseases* in 2 studies
1 review(s) available for lactoferrin and Nervous-System-Diseases
Article | Year |
---|---|
Salivary biomarkers for the diagnosis and monitoring of neurological diseases.
Current research efforts on neurological diseases are focused on identifying novel disease biomarkers to aid in diagnosis, provide accurate prognostic information and monitor disease progression. With advances in detection and quantification methods in genomics, proteomics and metabolomics, saliva has emerged as a good source of samples for detection of disease biomarkers. Obtaining a sample of saliva offers multiple advantages over the currently tested biological fluids as it is a non-invasive, painless and simple procedure that does not require expert training or harbour undesirable side effects for the patients. Here, we review the existing literature on salivary biomarkers and examine their validity in diagnosing and monitoring neurodegenerative and neuropsychiatric disorders such as autism and Alzheimer's, Parkinson's and Huntington's disease. Based on the available research, amyloid beta peptide, tau protein, lactoferrin, alpha-synuclein, DJ-1 protein, chromogranin A, huntingtin protein, DNA methylation disruptions, and micro-RNA profiles provide display a reliable degree of consistency and validity as disease biomarkers. Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Biomarkers; DNA Methylation; Humans; Lactoferrin; Nervous System Diseases; Oxidative Stress; Protein Deglycase DJ-1; Saliva; tau Proteins | 2018 |
1 other study(ies) available for lactoferrin and Nervous-System-Diseases
Article | Year |
---|---|
Elevated CSF lactoferrin in superficial siderosis of the central nervous system.
This study sought to identify abnormalities in the levels of iron transport proteins in patients with superficial siderosis of the central nervous system. We compared patients with superficial siderosis (n = 7) with patients suffering from various other neurological disorders (n = 176, total). CSF and serum levels of lactoferrin, and CSF levels of transferrin were measured by enzyme-linked immunosorbent assay. Serum transferrin was measured by nephelometry. Lactoferrin, but not transferrin, levels in the CSF were significantly elevated in superficial siderosis. Unexpectedly, CSF transferrin was decreased in multiple sclerosis patients. Enhanced CSF lactoferrin may reflect an increased iron transport requirement in the central nervous system in superficial siderosis and might be a useful measure for monitoring response to therapy. Topics: Central Nervous System Diseases; Humans; Lactoferrin; Meningitis, Bacterial; Multiple Sclerosis; Nervous System Diseases; Siderosis; Transferrin | 1999 |